Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Neurology

• Publication date

  2017-05-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00415-017-8514-zPMID 28516329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study.

  2016cited by this paper
• Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.

  2016cited by this paper
• Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen.

  2016cited by this paper
• Myasthenia gravis and risks for comorbidity

  2015cited by this paper
• Characteristics of myasthenia gravis with antibodies to muscle‐specific kinase and low‐density lipoprotein‐related receptor protein 4

  2015cited by this paper
• Clinical application of clustered-AChR for the detection of SNMG

  2015cited by this paper
• Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis.

  2015cited by this paper
• MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study.

  2015cited by this paper
• Do associated auto-antibodies influence the outcome of myasthenia gravis after thymectomy?

  2015cited by this paper
• Anti-agrin autoantibodies in myasthenia gravis

  2014cited by this paper
• Autoantibodies to Agrin in Myasthenia Gravis Patients

  2014cited by this paper
• A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.

  2014cited by this paper
• Cortactin autoantibodies in myasthenia gravis.

  2014cited by this paper
• Antibodies to clustered acetylcholine receptor: expanding the phenotype

  2014cited by this paper
• Antititin antibody in early‐ and late‐onset myasthenia gravis

  2014cited by this paper
• Clinical features of myasthenia gravis patients with autoimmune thyroid disease in Taiwan

  2013cited by this paper
• Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

  2013cited by this paper
• Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis.

  2013cited by this paper
• Structural basis of agrin-LRP4-MuSK signaling.

  2012cited by this paper
• Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis.

  2012cited by this paper
• Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.

  2012cited by this paper
• Diagnostik und Evaluation – zähneknirschend oder neugierig?

  2012cited by this paper
• The search for new antigenic targets in myasthenia gravis

  2012cited by this paper
• Updated assessment of the prevalence, spectrum and case definition of autoimmune disease.

  2012cited by this paper
• Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis

  2012cited by this paper
• Frequency of Autoimmune Diseases in Myasthenia Gravis: A Systematic Review

  2011cited by this paper
• Three Types of Striational Antibodies in Myasthenia Gravis

  2011cited by this paper
• Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis

  2011cited by this paper
• Beck Depression Inventory–II

  2011cited by this paper
• Autoimmune mediated neuromuscular junction defects.

  2010cited by this paper
• When to consider thyroid dysfunction in the neurology clinic

  2009cited by this paper
• Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

  2009cited by this paper
• Myasthenia Gravis in the Elderly

  2008cited by this paper
• IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†

  2008cited by this paper
• Lrp4 is a receptor for Agrin and forms a complex with MuSK.

  2008cited by this paper
• Clinical features of patients with myasthenia gravis associated with autoimmune diseases

  2007cited by this paper
• Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease

  2006cited by this paper
• The significance of titin antibodies in myasthenia gravis

  2004cited by this paper
• Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.

  2003cited by this paper
• Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.

  2003cited by this paper
• Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

  2003cited by this paper
• The occurrence of anti-titin antibodies and thymomas: A population survey of MG 1970–1999

  2002cited by this paper
• Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients.

  2001cited by this paper
• Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies

  2001cited by this paper
• Myasthenia gravis

  2000cited by this paper
• Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

  2000cited by this paper
• Muscle autoantibodies in subgroups of myasthenia gravis patients

  2000cited by this paper
• Myasthenia gravis: recommendations for clinical research standards1

  2000cited by this paper
• The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo.

  1996cited by this paper
• Titin antibodies in patients with late onset myasthenia gravis: clinical correlations.

  1995cited by this paper
• Clinical heterogeneity of seronegative myasthenia gravis.

  1994cited by this paper
• Titin antibodies in myasthenia gravis

  1993cited by this paper
• Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis.

  1982cited by this paper
• Antibody to acetylcholine receptor in myasthenia gravis

  1976cited by this paper

• Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis

  2026cites this paper
• Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data

  2025cites this paper
• Development and Application of a Cell-Based Assay for Detecting Anti-Agrin Antibodies Associated With Myasthenia Gravis

  2025cites this paper
• Clinical utility of autoantibodies in the diagnosis and management of Myasthenia gravis.

  2025cites this paper
• Myasthenia Gravis - An Updated Review.

  2025cites this paper
• Clinical characteristics of myasthenia gravis patients with coexistence of AChR and titin antibodies

  2025cites this paper
• Serum neurofilament light chain levels in myasthenia gravis patients with and without symptoms

  2025cites this paper
• Comparison of three methods for the detection of antibodies against muscle-specific kinase.

  2024cites this paper
• The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments.

  2024cites this paper
• Anti-titin antibodies in a cohort of myasthenia gravis patients

  2024cites this paper
• Diaphragmatic Palsy Due to a Paraneoplastic Autoimmune Syndrome Revealed by Checkpoint Inhibitors

  2024cites this paper
• Female sex and overweight are associated with a lower quality of life in patients with myasthenia gravis: a single center cohort study

  2023cites this paper
• Bidirectional association between hypothyroidism and myasthenia gravis: a Mendelian randomized study

  2023cites this paper
• Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody

  2022cites this paper
• Overview of biomarkers in myasthenia gravis

  2022cites this paper
• Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal

  2022cites this paper
• Different Monoclonal Antibodies in Myasthenia Gravis: A Bayesian Network Meta-Analysis

  2022cites this paper
• Improving laboratory diagnostics in myasthenia gravis

  2021cites this paper
• Comorbid Autoimmune Diseases in Patients With Myasthenia Gravis: A Retrospective Cross-Sectional Study of a Chinese Cohort

  2021cites this paper
• Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis.

  2021cites this paper
• Myasthenia gravis genome-wide association study implicates AGRN as a risk locus

  2021cites this paper
• Tolosa-Hunt syndrome with general myasthenia gravis involvement.

  2020cites this paper
• Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics

  2020cites this paper
• Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability

  2020cites this paper
• Clinical features of LRP4/agrin‐antibody–positive myasthenia gravis: A multicenter study

  2020cites this paper
• A Myasthenia Gravis genomewide association study of three cohorts identifies Agrin as a novel risk locus.

  2020cites this paper
• Myasthenic Syndromes

  2020cites this paper
• Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management

  2020cites this paper
• Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies

  2020cites this paper
• Reduced plasmablast frequency is associated with seronegative myasthenia gravis

  2020cites this paper
• Epstein-Barr Virus in Myasthenia Gravis: Key Contributing Factor Linking Innate Immunity with B-Cell-Mediated Autoimmunity

  2020cites this paper
• Autoimmune Ocular Myasthenia Gravis: Diagnostic Utility of Autoantibodies to The Neuromuscular Junction in Eye Disorders

  2020cites this paper
• Autoantibodies in acquired myasthenia gravis: Clinical phenotype and immunological correlation

  2019cites this paper
• Clinical analysis of Chinese anti‐low‐density‐lipoprotein‐receptor‐associated protein 4 antibodies in patients with myasthenia gravis

  2019cites this paper
• Thyroid disorders in patients with myasthenia gravis: A systematic review and meta-analysis.

  2019cites this paper
• Muskelerkrankungen

  2019cites this paper
• Collagen XIII and Other ECM Components in the Assembly and Disease of the Neuromuscular Junction

  2019cites this paper
• Diagnosis of Myasthenia Gravis

  2018cites this paper
• Diagnosis of Myasthenia Gravis

  2018cites this paper
• Diagnosis of Myasthenia Gravis

  2018cites this paper
• Diagnosis of Myasthenia Gravis

  2018cites this paper
• Late-onset Myasthenia Gravis Accompanied by Amyotrophic Lateral Sclerosis with Antibodies against the Acetylcholine Receptor and Low-density Lipoprotein Receptor-related Protein 4

  2018cites this paper
• Myasthenia gravis: from autoantibodies to therapy

  2018cites this paper
• Myasthenia gravis: the unmet needs of a paradigmatic autoimmune disease.

  2018cites this paper
• Serological and experimental studies in different forms of myasthenia gravis

  2018cites this paper
• Introducing Autoimmunity at the Synapse by a Novel Animal Model of Experimental Autoimmune Myasthenia Gravis.

  2018cites this paper
• MuSK and Myasthenia Gravis due to other Antibodies

  2018cites this paper
• Myasthenia gravis: aktuelle Antikörperdiagnostik und Aspekte zum therapierefraktären Verlauf

  2018cites this paper
• Diagnostik der Myasthenia gravis

  2018cites this paper
• Diagnosis of Myasthenia Gravis

  2018cites this paper
• Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis

  2018cites this paper
• Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

  2018cites this paper
• Diagnosis of Myasthenia Gravis

  2018cites this paper
• Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders

  2017cites this paper
• [Seronegative myasthenia gravis].

  2017cites this paper